Slide 1: Preliminary Year End Results
Vita Life Sciences Limited ASX Code: VSC Preliminary Year End Results 31 December 2010
Slide 2: Brands
Brands Australia Y Y Malaysia Y Y Singapore Y Thailand Y Y China Y Y Indonesia Y Vietnam Y 1
Slide 3: Sales Trend, Debt Levels and Normalised EBIT
Sales Trend, Debt Levels and Normalised EBIT 20.2 $ ' Millions 17.0 14.4 11.8 2007 2008 2009 2010 Events Relisted on ASX Focus on sales growth Health division profitable Health division profitable Debt ($ ’m) 0.8 1.3 1.3 1.8 * Normalised EBIT ($’m) (0.5) (0.6) 0.5 0.8 * At 31 December 2010, Vita Lif
Slide 4: Product Reach
Product Reach • In Australia –products are sold in over 600 health food stores; • In Malaysia – products are sold in 3 main channels over-the-counter (>800 stores), no-frills and multi-level marketing; • In Singapore – VH products are sold in over 200 stores • In China, Thailand and Indonesia – less
Slide 5: Sales Revenue
Sales Revenue 25 20.2 20 • Sales grew by 18.7% 17.0 14.4 in 2010 (2009: 18.5%) A$ million 15 11.8 • Sales growth y-o-y for 10 Australia, Malaysia and Singapore were 5 13.4%, 31.3% and 0 6.0% respectively 2007 2008 2009 2010 4
Slide 6: Sales Revenue - Segment
Sales Revenue - Segment 2010 2009 Singapore Singapore 17% 20% Others Others 2% Australia 1% Australia 47% 49% Malaysia 34% Malaysia 30% 5
Slide 7: Normalised Profit
Normalised Profit Income Statement ($ m) 2010 2009 % Change EBIT 4.9 (0.1) >100% Add / (less): Pan Case net receipts / (costs) (4.1) 0.6 Normalised EBIT 0.8 0.5 50% Interest expense (0.3) (0.2) Income tax expense (0.2) 0.0 Normalised net profit after tax 0.4 0.3 16% Normalised EPS 0.7 cts 0.6 cts 9%
Slide 8: Normalised EBIT
1.00 Normalised EBIT 0.8 0.80 0.60 0.5 0.40 A$ million 0.20 (0.6) (0.5) - -0.20 -0.40 -0.60 Year 2007 2008 2009 2010 1. Excluding proceeds, net of costs, from Pan Case of $0.01 million, $0.41 million, and $4.1 million in 2007, 2008 and 2010 respectively. In 2009, Pan Case cost were $0.63 million 2.
Slide 9: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet At 31 December ($ m) 2010 2009 Current assets 12.2 6.6 Non-current assets 2.3 2.2 Total assets 14.5 8.8 Current liabilities (6.4) (4.9) Non-current liabilities (0.0) (0.0) Total liabilities (6.4) (4.9) Net assets 8.1 3.9 8
Slide 10: Other
Other • Group has an equity interest of 6.3% (20.1% profit share) in a property project in Malaysia; • Project has a positive cash flow; • No funding required from Group. 9
Slide 11: Health Division Outlook for 2011
Health Division Outlook for 2011 • Sales trends forecast to continue • Controlling operating expenditures • Continue to invest 30% – 40% of operating profits in new businesses • Improved profitability after investment in new businesses 10
Slide 12: Shareholder Information Ordinary shares
Shareholder InformationOrdinary shares Percentage Number held Ten largest quoted equity security holders of shares (million) issued Chemical Trustee Limited 8.6 15.8% Stinoc Pty Limited (a subsidiary of CVC Limited) 8.0 14.8% Barings Acceptance Limited 7.4 13.6% Llyods & Casanove Investment Partners
Slide 13: Thank You
Thank You 25 February 2011 ® Powered Templates.com